Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737178 | 0.77 | KDM4E (0.44) | BACE1 | |
| SCHEMBL4527945 | 0.76 | SCN9A (0.36) | — | |
| SCHEMBL4528927 | 0.71 | CTSD (0.31) | — | |
| SCHEMBL7003125 | 0.65 | KCNH2 (0.48) | KCNH2HDAC1HDAC2HDAC3LTA4H | |
| SCHEMBL338810 | 0.64 | LTA4H (0.70) | KCNH2HDAC2LTA4HPRMT6 | |
| SCHEMBL830311 | 0.63 | LTA4H (0.63) | KCNH2HDAC1HDAC2HDAC3LTA4H | |
| SCHEMBL1334921 | 0.62 | KCNH2 (0.59) | KCNH2LTA4HPRMT6 | |
| SCHEMBL13376370 | 0.62 | KCNH2 (0.51) | KCNH2HDAC1HDAC2HDAC3LTA4H | |
| SCHEMBL13706069 | 0.62 | KCNH2 (0.51) | KCNH2HDAC1HDAC2HDAC3LTA4H | |
| SCHEMBL7455134 | 0.62 | LTA4H (0.67) | KCNH2HDAC2LTA4HPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | claimed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | KCNH2 3854/4885BACE1 3629/4885HDAC1 1548/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | KCNH2 3854/4885BACE1 3629/4885HDAC1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.